EE03031B1 - Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid - Google Patents

Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid

Info

Publication number
EE03031B1
EE03031B1 EE9400328A EE9400328A EE03031B1 EE 03031 B1 EE03031 B1 EE 03031B1 EE 9400328 A EE9400328 A EE 9400328A EE 9400328 A EE9400328 A EE 9400328A EE 03031 B1 EE03031 B1 EE 03031B1
Authority
EE
Estonia
Prior art keywords
antigen
monoclonal antibody
carbogen
tumor
pharmaceutical compositions
Prior art date
Application number
EE9400328A
Other languages
English (en)
Estonian (et)
Inventor
Lindholm Leif
Holmgren Jan
Lind Peter
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of EE03031B1 publication Critical patent/EE03031B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EE9400328A 1991-07-03 1994-11-16 Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid EE03031B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody

Publications (1)

Publication Number Publication Date
EE03031B1 true EE03031B1 (et) 1997-08-15

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400328A EE03031B1 (et) 1991-07-03 1994-11-16 Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid

Country Status (19)

Country Link
US (1) US5552293A (enExample)
EP (1) EP0521842B1 (enExample)
JP (1) JP3194020B2 (enExample)
KR (1) KR100246681B1 (enExample)
AT (1) ATE171193T1 (enExample)
AU (2) AU658198B2 (enExample)
CA (1) CA2073124C (enExample)
DE (1) DE69226990T2 (enExample)
DK (1) DK0521842T3 (enExample)
EE (1) EE03031B1 (enExample)
ES (1) ES2124250T3 (enExample)
FI (1) FI109207B (enExample)
HU (2) HU218084B (enExample)
IE (1) IE80841B1 (enExample)
IL (1) IL102390A (enExample)
NO (1) NO315472B1 (enExample)
NZ (1) NZ243435A (enExample)
SE (1) SE9102074D0 (enExample)
WO (2) WO1993001302A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
ES2172149T3 (es) * 1997-04-14 2002-09-16 Micromet Ag Nuevo metodo para la produccion de receptores de antigeno anti-humano y sus usos.
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2002074251A2 (en) 2001-03-15 2002-09-26 International Bioimmune Systems, Inc. Monoclonal antibody therapy for pancreas cancer
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
EP1539239A4 (en) * 2002-07-02 2005-09-14 Smithkline Beecham Corp NEW STABLE FORMULATION
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CR20170291A (es) 2003-05-20 2017-07-27 Immunogen Inc Agentes citotoxicos mejorados que comprenden nuevos maitansinóides
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
BRPI0614366A2 (pt) * 2005-08-11 2009-10-06 Arpi Matossian Rogers peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos
AU2012244244B2 (en) * 2005-08-11 2015-08-27 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
CN101267841B (zh) 2005-08-24 2012-10-10 免疫原公司 制备美登木素生物碱抗体缀合物的方法
DK2325648T3 (da) 2008-08-05 2014-07-28 Toray Industries Fremgangsmåde til detektering af cancer
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
MX339927B (es) 2011-03-29 2016-06-16 Immunogen Inc Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa.
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
KR20170088905A (ko) 2014-11-19 2017-08-02 이뮤노젠 아이엔씨 세포 결합 작용제-세포독성 작용제 접합체를 제조하기 위한 공정
CA3010678A1 (en) 2016-01-10 2017-07-20 Neotx Therapeutics Ltd. Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
US20210299265A1 (en) 2016-02-05 2021-09-30 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
US20200256880A1 (en) * 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin
EP3969043A1 (en) 2019-05-15 2022-03-23 Neotx Therapeutics Ltd. Cancer treatment
EP4114449A2 (en) 2020-03-05 2023-01-11 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
WO1992001470A1 (en) * 1990-07-20 1992-02-06 Kabi Pharmacia Ab Target specific antibody-superantigen conjugates and their preparation
CA2087163A1 (en) * 1990-07-20 1992-01-21 Hubert Agback Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures

Also Published As

Publication number Publication date
EP0521842A2 (en) 1993-01-07
IL102390A0 (en) 1993-01-14
HUT71193A (en) 1995-11-28
AU658198B2 (en) 1995-04-06
ES2124250T3 (es) 1999-02-01
HU218084B (hu) 2000-05-28
DE69226990D1 (de) 1998-10-22
NO934777D0 (no) 1993-12-22
FI935970A0 (fi) 1993-12-31
ATE171193T1 (de) 1998-10-15
FI935970L (fi) 1993-12-31
AU2292092A (en) 1993-02-11
AU1942592A (en) 1993-01-07
EP0521842A3 (enExample) 1994-01-26
NO315472B1 (no) 2003-09-08
US5552293A (en) 1996-09-03
IE922188A1 (en) 1993-01-13
DE69226990T2 (de) 1999-03-25
KR100246681B1 (ko) 2000-04-01
WO1993001303A1 (en) 1993-01-21
IE80841B1 (en) 1999-03-24
HU211512A9 (en) 1995-11-28
DK0521842T3 (da) 1999-06-14
JPH05276987A (ja) 1993-10-26
JP3194020B2 (ja) 2001-07-30
FI109207B (fi) 2002-06-14
HU9400011D0 (en) 1994-05-30
NO934777L (no) 1994-02-11
CA2073124C (en) 2007-06-19
IL102390A (en) 1996-01-19
EP0521842B1 (en) 1998-09-16
CA2073124A1 (en) 1993-01-04
WO1993001302A1 (en) 1993-01-21
SE9102074D0 (sv) 1991-07-03
NZ243435A (en) 1994-10-26

Similar Documents

Publication Publication Date Title
EE03031B1 (et) Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid
FI101937B1 (fi) Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmisen cachectiinin kanssa
FI912016L (fi) In vitro -menetelmä antigeenispesifisten ihmisen monoklonaalisten vasta-aineiden valmistamiseksi
ATE13317T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches prothymozytantigen; antikoerper und verfahren zu seiner herstellung; diagnostische und therapeutische verwendungen und diesen antikoerper enthaltende pharmazeutische zusammensetzungen.
GR3020108T3 (en) Monoclonal antibody reactive with a novel HLA determinant on MHC class I molecules and method for activating lymphocytes
ES2181674T3 (es) Dominios de union en las proteinas notch y delta.
TR199800607T1 (xx) Dendritik h�cre uyar�c� fakt�r�.
ATE113845T1 (de) Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.
IL74156A (en) Method for the preparation of a monoclonal antibody and of an immortalized cell producing the same and pharmaceutical compositions containing the monoclonal antibody
DE69127487D1 (de) Verfahren zum Nachweis der Alzheimer-Krankheit
JPS5726623A (en) Vaccine and manufacture
IT7920789A0 (it) Metodo e mezzo per regolare l'uniformita' dello stiramento di nastri.
DE3583265D1 (de) Tumortherapeutikum und verfahren zu seiner herstellung.
DE69015230D1 (de) Antikörper gegen menschliches Sperma, ihre Herstellung und Anwendung.
DE3688204D1 (de) Monoklonaler antikoerper gegen ein p21-bezuegliches dodekapeptid des ras-onkogens.
ATE103989T1 (de) Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung.
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
ATE243742T1 (de) Hybridzelle und deren verwendung zur herstellung eines arzneimittels zur induktion einer tumorimmunität
AU2484488A (en) Method for the production of antigenic protein-hapten conjugates, and antibodies corresponding thereto
ES2053507T3 (es) Un metodo para producir anticuerpos lym-2.
BG51640A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody against antigenous determinant, common for the strains " hantaan " and " bulgarian " of the virus of haemorrhagic fever with nephritic syndrome
BG51731A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody against antigenic deternimant, common for the strains hantaan and finnish of the virus of haemorrhagic fever with nephritic syndrome
DK182188A (da) Humant tumorassocieret antigen
IT8020164A0 (it) Procedimento per produrre colture sporifere di un ceppo di clavicepspurpurea virulento sulla segale e producente l'ergocristina.

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

MM4A Lapsed by not paying the annual fees

Effective date: 20071116